Progression and survival in Parkinson's disease
Identifieur interne : 002686 ( Main/Exploration ); précédent : 002685; suivant : 002687Progression and survival in Parkinson's disease
Auteurs : R. J. Marttila [Finlande] ; U. K. Rinne [Finlande] ; R. J. Marttila [Finlande]Source :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1991-10.
English descriptors
- KwdEn :
Abstract
Parkinson's disease is a progressive disorder and no permanent cure has ever been documented. The clinical onset, which usually occurs at an age of 55–65 years, is probably preceded by a preclinical period of two or more decades. The progression rate of the disease is extremely variable in different patients; in individual patients on the other hand, the progression of motor symptoms is fairly constant. The tremor‐dominant type of the disease usually has a more favourable prognosis than the hypokinetic type. Onset at an older age may be associated with a faster progression rate and the development of cognitive failure. In natural conditions, the average duration of Parkinson's disease is 10 years, although with a considerable range. The disease shortens life expectancy, which can be restored at least partially by treating patients with levodopa and other modern drugs. The highest benefit in increasing life expectancy is obtained when the treatment is initiated at a relatively early stage of the disease.
Url:
DOI: 10.1111/j.1600-0404.1991.tb05016.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Progression and survival in Parkinson's disease</title><author><name sortKey="Marttila, R J" sort="Marttila, R J" uniqKey="Marttila R" first="R. J." last="Marttila">R. J. Marttila</name></author><author><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name></author><author><name sortKey="Marttila, R J" sort="Marttila, R J" uniqKey="Marttila R" first="R. J." last="Marttila">R. J. Marttila</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BF06C835D2D040D55B336E2B6ECC60B342D2C3A7</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1111/j.1600-0404.1991.tb05016.x</idno><idno type="url">https://api.istex.fr/document/BF06C835D2D040D55B336E2B6ECC60B342D2C3A7/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000991</idno><idno type="wicri:Area/Main/Curation">000863</idno><idno type="wicri:Area/Main/Exploration">002686</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Progression and survival in Parkinson's disease</title><author><name sortKey="Marttila, R J" sort="Marttila, R J" uniqKey="Marttila R" first="R. J." last="Marttila">R. J. Marttila</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Marttila, R J" sort="Marttila, R J" uniqKey="Marttila R" first="R. J." last="Marttila">R. J. Marttila</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, University of Turku, SF‐20520 Turku</wicri:regionArea><orgName type="university">Université de Turku</orgName><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1991-10">1991-10</date><biblScope unit="volume">84</biblScope><biblScope unit="issue">S136</biblScope><biblScope unit="page" from="24">24</biblScope><biblScope unit="page" to="28">28</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">BF06C835D2D040D55B336E2B6ECC60B342D2C3A7</idno><idno type="DOI">10.1111/j.1600-0404.1991.tb05016.x</idno><idno type="ArticleID">ANE24</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>disability</term><term>mortality</term><term>progression</term><term>survival</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease is a progressive disorder and no permanent cure has ever been documented. The clinical onset, which usually occurs at an age of 55–65 years, is probably preceded by a preclinical period of two or more decades. The progression rate of the disease is extremely variable in different patients; in individual patients on the other hand, the progression of motor symptoms is fairly constant. The tremor‐dominant type of the disease usually has a more favourable prognosis than the hypokinetic type. Onset at an older age may be associated with a faster progression rate and the development of cognitive failure. In natural conditions, the average duration of Parkinson's disease is 10 years, although with a considerable range. The disease shortens life expectancy, which can be restored at least partially by treating patients with levodopa and other modern drugs. The highest benefit in increasing life expectancy is obtained when the treatment is initiated at a relatively early stage of the disease.</div></front></TEI><affiliations><list><country><li>Finlande</li></country><region><li>Finlande occidentale</li></region><settlement><li>Turku</li></settlement><orgName><li>Université de Turku</li></orgName></list><tree><country name="Finlande"><region name="Finlande occidentale"><name sortKey="Marttila, R J" sort="Marttila, R J" uniqKey="Marttila R" first="R. J." last="Marttila">R. J. Marttila</name></region><name sortKey="Marttila, R J" sort="Marttila, R J" uniqKey="Marttila R" first="R. J." last="Marttila">R. J. Marttila</name><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002686 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002686 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BF06C835D2D040D55B336E2B6ECC60B342D2C3A7
|texte= Progression and survival in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |